medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2011, Number 3

<< Back Next >>

VacciMonitor 2011; 20 (3)

Influence of mucosal immunization routes on herpes simplex virus type 2 protection with AFCol as adjuvant

Cabrera O, Cuello M, Thörn K, Lindqvist M, Lastre M, González E, Zayas C, Balboa J, Romeo B, Sarandi AM, Pérez O

Language: Spanish
References: 17
Page: 14-20
PDF size: 254.23 Kb.


ABSTRACT

Mucosal vaccines are a promising strategy to induce mucosal protection. Herpes simplex virus type 2 is the commonest pathogens in the human transmitted by exposure at the genital mucosal surfaces. Many vaccine candidates against this pathogen have been evaluated; but they have not been effective, and neither a prophylactic nor a therapeutic vaccine has been yet obtained. The gD2 is a recombinant glycoprotein and it is reported as one of the antigens of importance for vaccine against this virus. There is the cochleate (AFCo1) derived from proteoliposome of Neisseria meningitidis serogroup B. This cochleate has shown potentialities as adjuvant for several immunization routes. The objective of this study was to evaluate the protection induced in mice by the AFCo1-gD2 administered by different mucosal routes. Female mice C57BL/6 were used and immunized by: intranasal (IN), intravaginal (IVag), or intrarectal (IR) routes with AFCo1-gD2 or gD2 alone. The anti-gD2 IgG and specific cellular proliferation were determined and the viral replication in vaginal wash, the signs of disease and the protection against the viral challenge, were measured too. A significant anti-gD2 IgG response was obtained by all routes, although the IN route showed the highest values. Cellular proliferation was observed in cells of animals immunized IN and IVag route; but not by IR route. In addition, a higher protection (100%) in the animals immunized with AFCo1-gD2 by IN route was observed. In conclusion the intranasal is the most promising route in the protection induction against this viral challenge.


REFERENCES

  1. Cooper D, Mester JC, Guo M, Nasar F, SouzaV, Dispoto S, et al. Epitope mapping of full-length glycoprotein D from HSV- 2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junction. Cell Immunol 2006;239:113–20.

  2. Whitley RJ. Herpes simplex virus infection. Semin Pediatr Infect Dis 2002;13(1):6–11.

  3. Hagan DO, Goldbeck C, Ugozzoli M, Ott G, Burke RL. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex type 2 in guinea pigs. Vaccine 1999;17:2229–36.

  4. Roizman B, Knipe DM. Herpes simplex viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2001. p. 2399–459.

  5. Stanberry LR. Clinical trials of prophylactic and therapeutic Herpes Simplex Virus vaccine. HERPES 2004;11(Suppl 3):161A-169A.

  6. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003;16(1):96–113.

  7. Pérez O, Lastre M, Cabrera O, del Campo J, Bracho G, Cuello M. New Vaccines Require Potent Adjuvants like AFPL1 and AFCo1. Scandinavian Journal of Immunology 2007;66:271–7.

  8. O‘Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev 2003;2:727–35.

  9. Del Campo J, Lindqvist M, Cuello M, Bäckström M, Cabrera O, Persson J. Intranasal immunization with a proteoliposomederived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine 2010;28:1193–200.

  10. Harandi AM, Eriksson K, Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 2003;77: 953–62.

  11. Tengvall S, Josefsson A, Holmgren J, Harandi A M. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice. Journal of Reproductive Immunology 2005;68:53–69.

  12. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, and Harandi AM. Mucosal Administration of CpG Oligodeoxynucleotide Elicits Strong CC and CXC Chemokine Responses in the Vagina and Serves as a Potent Th1-Tilting Adjuvant for Recombinant gD2 Protein Vaccination against Genital Herpes. Journal of Virology 2006;80:5283–91.

  13. Cuello M, Cabrera O, Acevedo R, Núńez N, del Campo J, Lastre M. Nasal immunization with AFCo1 induces immune response to N. gonorrhoea in mice. Vaccimonitor 2009;18(2):78-80.

  14. Del Campo J, Zayas C, Romeu B, Acevedo R, González E, Bracho G. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitis serogroup B induce mucosal and systemic responses. Methods 2009;49(4):301–8.

  15. Belyakov IM and Ahlers JD. What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal? J Immunol 2009;183:6883-92.

  16. Mohammad J, Hoorieh S, Fatemeh F, Pakravan N. Comparison of intramuscular and footpad subcutaneous Immunization with DNA vaccine encoding HSV-gD2 in mice. Comparative Immunology, Microbiology and Infectious Diseases 2009; 32(5):453-61.

  17. Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR. Immunology Mucosal. 2da ed. London: Academia Press; 1999.




2020     |     www.medigraphic.com